CACrown ArchivesThe cinema collection
EN/FR
Search
Menu
Research dossier · Science & Nature

Motexafin lutetium

chemical compound

Specimen drawers, botanical folios and brass scientific instruments under study light
Science and natureInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionAug 10, 2026
Entity authorityQ6917197 ↗
Source-derived summary

Motexafin lutetium is a texaphyrin, developed by Pharmacyclics Inc. (proposed trade names Lutrin, Antrin and Optrin)

It is a photosensitiser for use in photodynamic therapy to treat skin conditions and superficial cancers.

It has also been tested for use in photoangioplasty (photodynamic treatment of diseased arteries).

It is photoactivated by 732 nm light which allows greater depth of penetration.

Clinical trials

Phase II clinical trials were in progress in 1999.

A phase I trial for prostate cancer reported in 2009.

As of 2017, this drug is no longer being developed.

Editorial summary

This brief starts where responsible research should: with the source description of “Motexafin lutetium” as chemical compound. Everything that follows is an evidence route, not borrowed authority.

Editorial reviewA sound reference starting point where classification, measurement and the date of the underlying evidence remain visible. The current lead gives the account dated anchors—1999, 2009, 2017—that can be checked directly. The selected authority fields contribute no independent date. The account is most persuasive where Motexafin, lutetium and chemical can be independently traced.
Editorial analysis

Why this record matters

The subject matters to the science & nature register because the source frames it as chemical compound. Its deeper value depends on whether names, dates, institutions and citations support that framing.

Evidence profile

Datasets, specimens, observations and peer-reviewed methods provide the appropriate test for the technical claims summarized here. The source revision retrieved here is dated Aug 10, 2026. The linked authority identifier is Q6917197. None of the 0 selected statements returned an explicit reference. The first chronological checks are 1999, 2009 and 2017.

Critical limits

Scientific names, classifications and consensus can change while older terminology persists in catalogues and historical literature. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.

Best used for
  • Current terminology
  • Classification context
  • Finding cited technical literature
Verify next

Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.

Three-step research path

  1. Establish the record: confirm the title “Motexafin lutetium”, its source revision and the description used here.
  2. Expand the search: follow Motexafin lutetium primary sources, Motexafin lutetium archive and Motexafin research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “Motexafin lutetium”?
  2. Has classification or technical consensus changed since the cited source?
  3. Is the terminology current, historical or disputed?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from “Motexafin lutetium” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.